Eczema & Dermatitis | NYU Langone Health
Dermatologists at NYU Langone are specialists in diagnosing and treating the types of skin irritation known as eczema and dermatitis.
Educational Resources for Children with Cancer & Blood Disorders | NYU Langone Health
At NYU Langone’s Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders, we aid children’s education during treatment.
Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device Short Title: TRISCEND II Pivotal Trial
The objectives of this clinical study are to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system with OMT compared to OMT alone in the treatment of patients with at least severe tricuspid regurgitation (TR).a
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A prospective multicenter randomized controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to Abbott MitraClip in patients with mitral regurgitation
This is a prospective, multicenter, randomized, parallel-group study to compare the safety and effectiveness of the PASCAL System to the MitraClip System for reduction of degenerative mitral regurgitation.
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A prospective multicenter randomized controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to Abbott MitraClip in patients with mitral regurgitation.
The Edwards PASCAL provides a transcatheter treatment for patients suffering from mitral regurgitation.The Edwards PASCAL System was designed to provide physicians a system that is safe, easy to use, and designed to maximize MR reduction.The objectives of this pivotal clinical trial are to evaluate the safety and effectiveness of the PASCAL System for transcatheter mitral valve repair compared to the MitraClip system when treating patients with symptomatic degenerative mitral regurgitation (despite medical therapy) and who are considered to be candidates (by the Heart Team) for transcatheter mitral valve repair. Specifically, transcatheter mitral valve repair using the PASCAL System will be compared to the MitraClip System.
Effect of Internal Brace on Outcomes following ACL Reconstruction with BTB Autograft: A Randomized Controlled Trial
The purpose of this study is to compare anterior cruciate ligament (ACL) reconstruction with bone-tendon-bone (BTB) autograft (the type of knee surgery you will be having) and the use of an internal brace technique to ACL reconstruction with BTB autograft alone. We want to see if the internal brace improves knee stability. The internal brace is a strong piece of stitching that is put near the ACL graft, to provide additional stability to the knee. This technique is Food and Drug Administration (FDA) approved and used in accordance with its approved indication in the context of this research study.
Effectiveness and impact of counseling enhanced with electronic cigarettes for harm reduction in smokers with opioid use disorder
We are conducting a research study to compare the effectiveness of telehealth counseling plus electronic cigarettes VERSUS telehealth counseling plus nicotine replacement therapy (patches and lozenges) in cigarette smoking reduction among adults who smoke cigarettes and also are in formal treatment for opioid use disorder. The baseline and follow-up visits must be done in person but the rest of the study is done remotely.
Effects of MRI Acceleration: Comparison with the Current NYU Standard
Magnetic resonance imaging can be acquired in different fashions. In recent times, a premium has been put on acceleration for various reasons, including patient comfort, decreasing motion, and increasing accessibility and availability. While the accelerated acquisition of MR images decreases acquisition time, there are effects on spatial and contrast resolution, which can influence image quality and ultimately diagnostic performance. NYU currently employs a low degree of MRI acceleration as our standard of care. However, multiple publications suggest that higher acceleration factors are possible without loss of diagnostic information but shorter MRI exams. Therefore, the purpose of this study is to evaluate the effects of faster image acceleration on image quality and diagnostic performance.
Effects of sleep among infants and toddlers on their neurodevelopmental outcomes
This study will examine the effects of infant and toddler sleep patterns among preterm and full-term infants on their neurodevelopmental outcomes following discharge from the neonatal intensive care unit (NICU). The purpose of this study is to assess infant and toddler sleep by way of parental completion of a validated questionnaire namely Brief Infant Sleep Questionnaire (BISQ) and identifying any potential correlating changes in the neurodevelopment using Bayley IV neurodevelopment assessment during their scheduled follow-up visit at neonatal follow-up clinic until 30 months of corrected age.
Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL)
The prevalence of Alzheimer disease (AD) is high and projected to increase. Further, epidemiological data suggests that ~15% of AD risk may be attributed to sleep problems. Obstructive sleep apnea (OSA) is common among the elderly (30-55%), and our prior work has established that cognitively normal older women with OSA have nearly double the 5-year risk of developing mild cognitive impairment (MCI) or dementia. Further, we showed that: i. OSA patients treated with positive airway pressure (PAP) experienced significant overnight increases in plasma neurofilament light (NfL), a marker of neural injury, with trends for AD-specific biomarkers (i.e. Aß40 and Tau) after PAP withdrawal; ii. OSA predicted longitudinal increases in AD biomarkers; and, iii. PAP treatment delayed the onset of MCI in subjects with reported OSA. There is therefore strong evidence suggesting that OSA treatment could be an important prevention strategy for AD. However, OSA trials to slow progression to AD face a number of challenges. First, the most effective therapy (i.e. PAP) has poor adherence. Second is defining the target population, prior trials targeted OSA patients with MCI/AD, who have advanced disease and could be less amenable to treatment. A third challenge is identifying cognitive testing that is sensitive to both sleep disruption and predictive of AD risk. (To better capture effects of OSA on the offline memory processing phase requires sleep-dependent memory paradigms, in which the encoding and recall are separated by a period of sleep with/without OSA). Finally, a randomized trial of sufficient duration to test the effects of treatment of OSA on risk of incident AD is currently not feasible. Our proposed trial, Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL), addresses these challenges. ESSENTIAL is a 5-year study of cognitively normal older adults with newly diagnosed OSA, ages 55-75, recruited from 4 well-established sleep clinics. OSA patients (n=200) will be randomized to either: i) a 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an “effective” improvement in the apnea-hypopnea index (AHI); ii) a waitlist control group to receive treatment at the conclusion of the 3-month intervention period. Effectively treated individuals (~150) and untreated individuals (~50 previously randomized +50 additionally-recruited untreated patients from the sleep clinic) will then be followed for up to 24 months to compare whether sustained improvements in AHI are associated with better cognitive function and AD biomarker change profiles as compared to untreated controls. Participants will undergo PSG, actigraphy, cognitive tests, and blood draws at baseline, 3 and 24 months. Our aims are to: 1) test 3-month differences in plasma AD biomarkers (NfL, p-tau, Aß) between those randomized to treatment and wait-list control groups; 2) test 3-month differences in cognition between the OSA treatment and wait-list control groups; 3) examine if sustained reduction in AHI over 24 months among effectively treated participants versus untreated controls is associated with better 24-month change profiles for AD biomarkers and cognition.